Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In this episode, Alicia Bigelow, ND joins to discuss the potential of psychedelic medicine to support the menopause transition. Dr. Ali Bigelow is a naturopathic physician, ketamine provider and licensed psilocybin facilitator in Portland, OR. She leads individual and group retreats, enjoys incorporating live music into her sessions when desired, and is passionate about supporting those navigating life transitions, such as end of life and menopause, through her low dose group, Menomorphosis. Dr. Bigelow will be doing retreats in 2026 with Rise Up Journeys at RiseUpJourneys.com In this conversation, Dr. Bigelow explores the emerging intersection between psychedelics and the menopausal transition, framing perimenopause and menopause as profound neuroendocrine, psychological, and existential shifts rather than merely clinical syndromes. She also discusses how hormonal changes—particularly declining estrogen—interact with serotonin, inflammation, and neuroplasticity, potentially shaping psychedelic experiences and outcomes. Throughout the discussion, Dr. Bigelow emphasizes the unique capacity of psychedelics to support self-actualization, identity reformation, and meaning-making during midlife, especially when combined with hormone therapy, intentional integration practices, and strong community support.   In this episode, you'll hear: Why perimenopause and menopause represent a major but under-recognized neurobiological life transition How estrogen, serotonin receptors, and psychedelics like psilocybin may interact in midlife What we know (and don't yet know) about hormone replacement therapy and psychedelic efficacy The potential anti-inflammatory effects of psychedelics and their relevance to menopausal symptoms How ketamine may function differently from classic psychedelics during hormonal transitions Why psychedelics can support identity reorientation, self-actualization, and "not caring" in generative ways The critical role of community, creativity, and nervous system regulation in integration during midlife   Quotes: "We don't honor and celebrate aging and elderhood overall in our culture. … What I do feel is really vital is that we gather and support each other in all of life's transitions, and [menopause has] not only been underrepresented, but also just under honored." [3:29] "As [estrogen] levels decrease, there's a decrease in serotonin receptors—which is the 5-HT2A receptor. And so that reduces our sensitivity to, and activity of serotonin. And psilocybin and LSD and other 5-HT2A agonists—they can enhance their receptors and the activity of those receptors." [13:20] "The understanding is that with [estrogen] hormone replacement therapy you would then, theoretically, see a replenishment of [serotonin] receptors, and then the psilocybin would have more ability to act on those receptors." [15:37] "Psilocybin—and psychedelics in general—and the menopausal transition are just really beautiful complements to each other and they become even more potent when used together." [19:48]   Links: Dr. Bigelow on LinkedIn Dr. Bigelow on Instagram Dr. Bigelow's website Synaptic Institute website  Rise Up Journeys website  Psychedelic Medicine Association Porangui

In this episode, Matthew W. Johnson, PhD returns to discuss how psychedelics can be leveraged to catalyze human agency. Dr. Johnson has been at the forefront of psychedelic research for 21 years, having conducted seminal research on the effects of psilocybin on mystical experience, personality, and treatment of cancer distress, major depressive disorder, and tobacco addiction. His work with tobacco addiction received the first federal funding for a classic psychedelic in the modern era of research. In this conversation, Dr. Johnson explores psychedelics as powerful enhancers of human agency—the felt capacity to steer one's own life, make meaningful choices, and act from a place of inner autonomy. Drawing from two decades of research across depression, cancer distress, addiction, and healthy volunteer studies, he argues that increases in agency may be a core, yet under-recognized, mechanism behind therapeutic change. Dr. Johnson discusses agency as a "meta-executive" function intertwined with free will, mental flexibility, and meaning-making, and suggests that psychedelics may uniquely illuminate and strengthen this capacity. In closing, he shares thoughts on how individuals can better take advantage of psychedelic-induced neuroplasticity to increase agency in their own lives.   In this episode, you'll hear: What Dr. Johnson means by "agency" and why he sees it as central to psychedelic healing Clinical examples of participants who rediscovered autonomy, changed behaviors, or reframed their suffering after psilocybin sessions Why psychedelics may enhance big-picture psychological flexibility, not just moment-to-moment cognitive flexibility How increased agency may help people with depression, addiction, and cancer distress shift entrenched patterns of thinking and behavior Potential future research directions for studying the neuroscience of agency   Quotes: "It's not just that enhancing agency is the elephant in the room of why psychedelics are working, it's also that I think psychedelics can be a tool for finally understanding this thing of human agency." [4:31] "Even if you think the sense of free will is an illusion, it has to be an evolutionarily advantageous illusion. Why else would it be seemingly universal?" [12:30] "When someone really has one of these 'ah-ha' experiences, they can really come to this perspective of 'no, no, no, no, no, I really am choosing how I'm thinking about myself.' In cancer [patients] it happened a lot." [21:51]   Links: Previous episode: The Latest Research on Psilocybin for Depression with Matthew Johnson, PhD Previous episode: Exploring DMT Entities with Matthew Johnson, PhD Previous episode: Avoiding the Pitfalls of Psychedelic Medicine with Matthew Johnson, PhD Dr. Johnson on X Dr. Johnson on InstagramDr. Johnson on LinkedIn Psychedelic Medicine Association Porangui

In this episode, Dmitry Repin, PhD joins to discuss the intersection of bodily movement and psychedelics. Dr. Repin is the co-founder of the Institute for Psychedelic Research at Tel Aviv University, holds a PhD in cognitive neuroscience, and is the producer and creative force behind the Everything Else Matters documentary. In this conversation, Dr. Repin explores how psychedelics may influence movement, proprioception, and motor learning, drawing from his background in neuroscience and his transformative experiences with dance practices like Gaga. He describes his team's innovative clinical study pairing psilocybin with guided movement training to investigate whether altered states can open temporary windows of enhanced plasticity for learning new movement patterns. Throughout the discussion, Dr. Repin reflects on why so many people feel inhibited in their bodies, how psychedelics might soften these constraints, and what traditional movement-based ceremonies can teach modern clinical research about embodiment, healing, and the relationship between perception and action.   In this episode, you'll hear: How dance and Gaga inspired Dr. Repin's scientific interest in movement during psychedelic states Kinesiophobia and why many people experience fear, shame, or inhibition around movement Why Dr. Repin chose psilocybin for his study on psychedelics and movement How Dr. Repin's study measures movement changes using optical tracking and multi-dimensional metrics What makes Gaga movement practices unique compared to other approaches to dance and movement The structure of the psilocybin-plus-movement protocol developed at Tel Aviv University How psychedelics may temporarily enhance motor learning through shifts in proprioception and neuroplasticity What ritual and communal dance contexts reveal about the embodied dimensions of psychedelic experiences   Quotes: "If we understand those [neurological] mechanisms, we can try to influence certain situations where people have deficits related to movement." [4:47] "For example, when I go to a dance training session [after a recent psychedelic experience], I find that I actually internalize movement patterns much faster than I do otherwise—and it's noticeable to my dance teacher." [8:56] "Part of the hypothesis that we have is that certain qualities or dimensions of movement might be affected more or less by psychedelics than others and that potentially, will give us some insights into the specific brain mechanisms because certain different types of movement sometimes require different circuits to engage in different parts of the body." [19:47] "Some initial wisdom, some anecdotes, or some best practices that have been developed within those non-clinical settings may be very useful to inform clinical—and maybe other—areas that use psychedelics." [27:03]   Links: Everything Else Matters documentary The Institute for Psychedelic Research at Tel Aviv University Dr. Repin on LinkedIn Dr. Repin on X Psychedelic Medicine Association Porangui

In this episode, Psychedelic Medicine Podcast host, Dr. Lynn Marie Morski, provides the latest updates from the field of psychedelic medicine. Dr. Morski discusses the breakthrough therapy designation which a number of psychedelic compounds have received in the past few years, the most recent of which is BPL-003, a nasal spray formulation of 5-MeO-DMT. One of the exciting aspects of this new compound, Dr. Morski notes, is that it is shorter-acting than most serotonergic psychedelics—a feature which may make treatment with this substance less expensive and more accessible.  Another exciting development is the COMPASS Pathways phase 3 trial of COMP360 psilocybin. Dr. Morski shares that the company believes they are nine to twelve months ahead of schedule, which means that if all goes well, this psilocybin compound could be approved for treatment resistant depression as early as sometime in 2027. She also discusses why the US FDA said they rejected MDMA for PTSD and what this governing body would like to see from subsequent research before reconsidering this decision. In closing, Dr. Morski shares excitement about the development of novel psychoplastogens—the non-hallucinogenic psychedelics—which may help bring many of the same healing benefits to populations currently unable to be served by the existing compounds under investigation.   In this episode, you'll hear: Which psychedelics currently have breakthrough therapy designation and for which indications Details of recent ketamine research for inpatient depression care and why these results are not as negative as they may seem The current horizons of psychedelic research and what indications may soon be explored Sources of hope in the current state of psychedelic research and the legal landscape   Quotes: "[BPL-003] showed rapid and durable antidepressant outcomes after a single dose. … here we have something that is under an hour [of psychedelic experience] for treatment resistant depression." [7:43] "Keeping patients blinded to whether or not they got the placebo or MDMA is a big focus that [the FDA] wanted to emphasize for these future phase 3 trials." [19:07] "I know we had a big setback last year. I think a lot of us thought by this time we'd be a year into MDMA being approved and we're not. However, there are so many things on the horizon that are worth being excited about." [23:48]   Links: Psychedelic Medicine Podcast on Instagram Psychedelic Medicine Podcast on YouTube Jelovac A, McCaffrey C, Terao M, et al. "Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial" JAMA Psychiatry, 2025. Beckley Psytech Limited Phase 2 Trial: BPL-003 Efficacy and Safety in Treatment Resistant Depression COMPASS Pathways Phase 3 Trial: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD Food and Drug Administration (FDA) Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy for Posttraumatic Stress Disorder Psychedelic Alpha Psychedelic Drug Development Bullseye Chart Psychedelic Medicine Association Porangui

In this episode Matthew Hicks, ND, MS joins to dive into the topic of psilocybin-assisted group therapy for depression. Dr. Hicks is a research Investigator at the National University of Natural Medicine as well as a Naturopathic doctor and licensed psilocybin facilitator at Synaptic Institute. In this conversation, Dr. Hicks shares findings from one of the first studies investigating psilocybin-assisted group therapy for depression, conducted in Oregon's new legal psilocybin framework. He explains how the high cost and labor-intensive nature of psychedelic therapy inspired him to explore a group model that could make treatment more financially accessible while preserving - and even enhancing - its therapeutic potential. Dr. Hicks describes the structure of the study and discusses how initial participant hesitancy about group work transformed into deep connection and shared healing. He also highlights the study's significant reductions in depression scores, improvements across quality-of-life measures, and the potential for group-based approaches to pave the way toward insurance reimbursement and broader access to psychedelic care.   In this episode, you'll hear: Why affordability and accessibility were central motivations for developing a group-based psilocybin protocol The benefits and challenges of conducting psilocybin sessions in a shared group setting How Dr. Hicks' study balanced inclusion of low-income participants with safety and stability criteria The details of the group treatment structure for Dr. Hicks' study Why Dr. Hicks believes group formats may be inherently therapeutic in addition to their economic efficiency Dr. Hicks's vision for future efficacy and cost-effectiveness studies that could enable insurance coverage   Quotes: "In terms of the group dynamic, almost everyone in the intake process was very reluctant. They were trepidatious. They were a little worried about the group part of it. And almost everybody at the end of it, when we did the follow ups at the group, was amazing. People made friends. They felt really supported. They felt really seen by the process of hearing other people's journeys and the growth that they went through—and seeing some other examples of transformation was really powerful and was really encouraging to me." [10:29] "So [there are] really positive aspects to doing this in a group format that's not just economic—it's not just cheaper to do this in group, it actually has therapeutic benefits that you miss out on when you only do this one on one." [11:12] "That was always my question in the follow up sessions: 'did your participation in this study change the way you engaged in psychotherapy? Did it change the relationship with your therapist?' And a lot of people reported that it did. They felt they were able to open up and engage more deeply, be more introspective. And it did, in many cases, not all, improve their psychotherapy outcomes as well." [18:24] "Some people reported that hearing someone else in the group crying for a bit really opened up something in them and they almost felt grateful for that. This other person is having a meaningful experience over there, and that's something they wouldn't have gotten on their own if they hadn't heard that person crying." [22:45]   Links: Dr. Hicks on LinkedIn Synaptic Institute website  Dr. Hicks' research at Synaptic Institute National University of Natural Medicine website  Psychedelic Medicine Association Porangui

In this episode Rotem Petranker, PhD joins to discuss the current state of research on microdosing psilocybin. Dr. Petranker is the co-founder of the Psychedelic Studies Research Program at the University of Toronto and the Canadian Centre for Psychedelic Science. He recently ran the world's largest randomized controlled trial on the effectiveness of microdosing psilocybin on Major Depressive Disorder. In this conversation, Dr. Petranker shares insights from running the world's largest randomized controlled trial on psilocybin microdosing for major depressive disorder. He explains the origins of microdosing research, from early anecdotes and surveys to his team's carefully designed clinical study comparing psilocybin to placebo across different environments. While participants in both groups reported significant improvements, the findings point to the powerful role of expectancy and placebo effects, alongside nuanced signals of cognitive shifts on measures like dysfunctional attitudes. Dr. Petranker emphasizes the importance of rigorous methodology, open science, and transparency in psychedelic research, while also acknowledging the stories of participants whose lives were positively impacted by study participation itself.   In this episode, you'll hear: What early microdosing research suggested, and its limitations in anecdotal and survey-based designs Why psilocybin was chosen over LSD for the study design  What motivates people to try microdosing a psychedelic Key results from Dr. Petranker's study, including reports of both positive and adverse events How placebo effects—and simply being part of a trial—can powerfully shape outcomes Reflections on how psychedelics may work by increasing connectedness   Quotes: "There's no real rigorous definition [of microdosing]. People say, 'oh, I'm just going to microdose some mushrooms,' and then they often take a random amount. I think what people mean is 'I'm going to take an amount that will not knock me out, won't cause serious hallucinations,' but they still use an amount that they often feel. Now, this is in contrast to what people in the [academic] literature define it as, which is more like a sub-perceptual dose, a sub-hallucinogenic dose." [2:17] "If you microdose and go to work, just to sit under the flickering lights for eight hours in your cubicle versus, say, if you're going to microdose and then go on a walk, or do art, or do as you wish because it's the weekend, you're going to have very different impacts on your anxiety." [15:26] "[In our study] there were three other self-report measures of depression. There is only a significant difference on one of them, where people who were microdosing were doing better. And that was on the dysfunctional attitude scale, which measures more cognitive assumptions about life." [26:2] "people who microdose—regardless of why they microdose—they more or less all said that they got to what they wanted through an increased sense of meaning." [35:05]   Links: Psychedelic Studies Research Program at the University of Toronto Canadian Centre for Psychedelic Science website Canadian Centre for Psychedelic Science on X Canadian Centre for Psychedelic Science on Instagram Previous episode: Microdosing and the Placebo Effect with Balazs Szigeti, PhD Previous episode: James Fadiman answers your Microdosing Questions! Psychedelic Medicine Association Porangui  

In this episode of the Psychedelic Medicine Podcast, Rick Strassman, MD joins to discuss the topic of endogenous DMT. Dr. Strassman is adjunct associate professor of psychiatry at the University of New Mexico in Albuquerque and author of DMT: The Spirit Molecule and The Psychedelic Handbook. His DMT and psilocybin studies in the early 1990s initiated the renewal of human research with psychedelics in the U.S. In this conversation, Dr. Strassman discusses the finer details of DMT, from endogenous production in humans and animals, to visionary experiences and theological implications. Dr. Strassman also covers the research that's been done regarding endogenous DMT, clarifying what we do and don't know about the role of the pineal gland and how this might relate to what is reported during near-death experiences. He also discusses the personal and relational quality of psychedelic experiences induced by DMT, mentioning that unitive mystical experiences were actually rare in the trials he conducted, with more experiences having a personal quality, drawing upon the life experiences and interests of the participants. In closing, Dr. Strassman shares his thoughts on the origins of the visions that many report during DMT use.    In this episode you'll hear: The overlap between psychedelic experiences and meditation techniques The relationship between fear, self-awareness, and difficult DMT experiences The placebo effect and psychedelic research Dr. Strassman's thoughts on non-hallucinogenic psychedelics DMT as a possible treatment for strokes to prevent damage and speed recovery Effects of microdosing in animals and humans   Quotes: "I think the best term for these compounds is psychedelic, which means mind manifesting or mind disclosing, because only one of our fifty-five or so normal volunteers had what one might call a mystical unitive state. … Everybody basically had an experience that was totally dependent on them. It was not inherent in the drug." [9:45] "You could still speculate that to the extent that non-drug states resemble those brought on by giving DMT… that DMT plays a role in the production of those states. But the data aren't there yet. That's why we need more people doing this research." [24:16] "If psychedelics are super placebos and if we have a psychedelic drug in our brain, it's attempting to speculate that normally the placebo effect could be mediated by endogenous DMT." [27:42] "If you starve neurons of oxygen they start dying, but if you add DMT they survive much longer. So there seems to be some neuroprotective effect of DMT on ischemic damage to neurons, at least in the test tube." [32:27]   Links: Dr. Strassman's website The Psychedelic Handbook by Dr. Strassman DMT: The Spirit Molecule by Dr. Strassman DMT and the Soul of Prophecy: A New Science of Spiritual Revelation in the Hebrew Bible by Dr. Strassman Dr. Strassman on FacebookPrevious episode: Exploring DMT Entities with Matthew Johnson, PhD Psychedelic Medicine Association Porangui

In this episode Steven Zeiler, MD, PhD joins to discuss the promise of psychedelics for stroke healing. Dr. Zeiler is an associate professor and physician at Johns Hopkins School of Medicine specializing in cerebrovascular disease, including acute stroke therapy, prevention, and recovery. He is a lead investigator for a Rose Hill Life Sciences research trial, conducted in partnership with Johns Hopkins University, exploring the use of psilocybin-assisted therapy to enhance motor function in patients with neurological injuries. In this conversation, Dr. Zeiler explains that after a stroke, there is a natural but time-limited critical period during which the brain is highly plastic and capable of repairing motor function. His research, inspired by work on psychedelics reopening critical learning windows, shows in animal models that a single high dose of psychedelics combined with intensive rehabilitation can restore lost motor abilities even after recovery has plateaued. Throughout, Dr. Zeiler emphasizes that psilocybin itself doesn't heal the brain directly but creates a window of heightened neuroplasticity that, when paired with targeted therapy, may dramatically improve recovery outcomes for stroke survivors.   In this episode, you'll hear: What happens to patients during a stroke The critical period of stroke recovery and how psychedelics may reopen this opportunity Why conducting a safety and tolerability study of psilocybin for stroke patients is crucial What forms of deficits and recoveries Dr. Zeiler's study will measure  Dr. Zeiler's speculations on what integrating psychedelic treatments into stroke medicine could look like The importance of specialized interventions that take advantage of the critical recovery period   Quotes: "What has been a little forgotten about in a lot of stroke management situations is helping the person get over the deficits with which the stroke has left them. And if you can't move an arm, you can't move a leg, that's a big deal. And we are not quite as good at addressing some of those problems." [5:11]  "[The potential of psychedelics for stroke recovery] is probably less about addressing the injury itself and more about helping the remaining parts of the brain turn on to address what's lost." [7:36] "We're not suggesting that the psychedelic itself has some sort of magical property that would just repair the brain, but it primes the situation to allow that input that we then provide over the next many days, many weeks, to affect a recovery." [13:31] "Imagine something as complicated as the brain going through a repair mechanism: could you imagine one molecule acting on one receptor being able to affect a recovery? I couldn't imagine that—it's too complicated a thing. And so having something like a mechanism of action that is acting through multiple pathways, I think has to be the case if we're going to affect something as complicated as brain repair." [17:30]   Links: Dr. Zeiler on LinkedIn Super Room for Enriched Neurological Repair at Green Spring (SENRG) PHATHOM (Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability)-Stroke Project Psychedelic Medicine Association Porangui

In this episode J. Ashley T. Booth, LCSW, MS joins to discuss the importance of long-term psychedelic integration. Ashley is a Los Angeles-based psychedelic therapist, IFS practitioner, and author of Quieting the Storm Within: An Illustrated Introduction to Your Parts Through Internal Family Systems and Beyond. With a background in research, education, and clinical work—including serving as a co-investigator on the MAPS MDMA trials—she specializes in helping clients integrate psychedelic experiences through compassionate parts work and Self-led healing. In this conversation, Ashley explores the nuances of psychedelic integration, discussing how this process can be supported through ongoing self-audits, somatic practices, and Internal Family Systems (IFS) work. She highlights the need to slow down, focus on one insight at a time, and anchor felt experiences into the body so they become lived behaviors rather than fleeting memories. The discussion also addresses challenges such as insufficient integration, psychedelic narcissism, and the pressure to "fix" oneself. In closing, Ashley stresses that even years after a journey, integration is possible if one revisits experiences with intention, and she underscores the central role of supportive communities in sustaining lasting transformation   In this episode, you'll hear: What things are important to focus on in long-term integration How someone can discern when their integration process has been sufficient to pursue a subsequent psychedelic journey  An overview of the internal family systems model of the psyche  The downsides of insufficient integration Developing deeper relationships with the parts of one's psyche through IFS Why it's never too late to integrate psychedelic experiences from one's past What to do when integration seems to come into conflict with feeling well adjusted to society's expectations   Quotes: "What I encourage clients to do is to take notes on everything that felt important and then separate them out into: 'I'm going to just focus on this one thing for like a month, and then maybe next month will be that second piece of it.' And so you're really allowing yourself to make particular practices and focus on one thing at a time." [6:21] "So whatever wound we're dealing with in our bodies, whether it's an extreme sort of big T trauma or little T trauma… there's a slowness that needs to happen. And so if there's parts of us that want to speed up that process, we need to be curious about that and see if there are ways that we can tend to that before the next journey." [13:59] "I think that part of the longer term questions are not just how we change our life but what kind of meaning are we making of our lives and how are we sitting more comfortably in that meaning in a way that is serving us and empowering us?" [25:52]   Links: Ashley's website IFS and Beyond on Instagram  IFS and Beyond website Quieting the Storm Within: An Illustrated Introduction to Your Parts Through Internal Family Systems and Beyond by J. Ashley T. Booth Aware Project: Southern California Psychedelic Society website Previous episode: Navigating Psychedelic Narcissism with Adam Aronovich Psychedelic Medicine Association Porangui  

In this episode, Dr. Genesee Herzberg joins to discuss the ways ketamine therapy can be combined with other healing modalities. Dr. Herzberg is a clinical psychologist and co-founder and director of Sage Integrative Health, an integrative psychedelic therapy clinic and training center in the SF Bay Area. She worked as a therapist on the MDMA for PTSD clinical trials and co-edited the book Integral Psychedelic Therapy. In this conversation, Dr. Herzberg explains how somatic therapy, touch therapy, bodywork, and movement support trauma processing. She also highlights the benefits of combining ketamine with acupuncture, craniosacral therapy, and functional medicine—including nutritional and hormonal assessments—to address physiological contributors to mental health. In closing, Dr. Herzberg emphasizes trauma-informed, team-based, and individualized approach to psychedelic healing, where ketamine acts as a bridge between psychological, somatic, and biomedical treatments.   In this episode, you'll hear: How somatic therapy is used within ketamine therapy sessions How ketamine helps quiet the default mode network to support therapeutic processing Ensuring safety during physical and movement-based therapies  The importance of establishing boundaries and explicit consent for therapeutic work that involves touch Dr. Herzberg's first hand experience of the reciprocal benefits of combining acupuncture and ketamine therapy Using functional medicine and nutrition therapy to support the therapeutic process with ketamine   Quotes: "I see ketamine, especially at lower psychoanalytic doses… as a support in turning down the volume on emotional and physical pain, which can then help us to better experience them. So I think of it as a sort of 're-associative'." [4:08] "Another aspect of the healing potential of therapy in general has to do with a therapeutic relationship: developing this sense that there's someone who cares about you, who's there to support you, who's going to be right there with you as you're dropping into your scariest and darkest places. And touch is one of the best ways to communicate that."  [13:53] "Acupuncture can help the nervous system to relax and help the system to open to the ketamine such that we are able to more fully receive the benefits of the medicine and feel the effects of it." [25:07]   Links: Sage Integrative Health website  Dr. Herzberg on LinkedIn  Sage Integrative Health on LinkedIn  Sage Integrative Health on Instagram Sage Integrative Health on Facebook   Integral Psychedelic Therapy: The Non-Ordinary Art of Psychospiritual Healing edited by Jason A. Butler, Genesee Herzberg, and Richard Louis Miller Previous episode: Psychedelic Adjunct Series: Somatic Therapy with Jenna Valentine, DACM, LAc Psychedelic Medicine Association Porangui  

In this episode, Charmaine Husum joins to discuss how art therapy can be a powerful tool for psychedelic preparation and integration. Charmaine is a Registered Art Therapist, Somatic Counsellor and Kundalini Yoga Teacher with over 12 years of experience supporting psychedelic preparation and integration. Her courses train professionals globally using specifically developed protocols in trauma-informed, harm-reduction practices, with her book, Psychedelics and Art Therapy: A Trauma-Informed Manual for Somatic Self Expression (Routledge, 2025), endorsed by numerous experts in the field including Stan and Brigitte Grof. In this discussion, Charmaine distinguishes between art as therapy and art therapy, emphasizing that the latter involves clinically informed, trauma-sensitive practices that externalize inner experiences to support healing. She outlines structured protocols used before and after psychedelic experiences, including creating visual representations of inner strength, setting intentions, and integrating experiences through multi-phase art exercises. Throughout, Charmaine emphasizes choice, embodiment, and the historical roots of art in altered states, offering a rich alternative for those seeking non-verbal, experiential ways to work through trauma and transformation.   In this episode, you'll hear: The types of art and materials employed in art therapy How art therapy can be employed to support preparation for a psychedelic experience Using art therapy for grounding and restabilization following an intense psychedelic journey Judith Herman's three stage model of healing trauma Why drawing a self portrait with one's non-dominant hand could be therapeutic Pursuing shadow work in art therapy Working with a client's perfectionism in art therapy   Quotes: "[Art therapy] is not about making art, actually. It's about being in the present moment, about moving materials, about allowing for often a cathartic release, and giving expression to what we often don't have words for." [3:14] "Art therapy isn't just about making the art, it's about processing the art afterwards." [7:48] "Art therapy is very helpful when we're trying to express something that's ineffable—something without words—which is… at the heart of psychedelics. There's often no words to describe what our experience has been. And so using creativity can be a real help there." [29:06]   Links: Centre of the HeArt website Centre of the HeArt on Instagram Centre of the HeArt on Facebook Charmaine on LinkedIn Charmaine's book: Psychedelics and Art Therapy: A Trauma-Informed Manual for Somatic Self Expression Psychedelic Medicine Association Porangui

In this episode, Seth Mehr, MD joins to share his expertise on safety planning prior to a patient undergoing psilocybin therapy. After a 20 year career as an Emergency Medicine physician, Seth founded Cascade Psychedelic Medicine in 2021, treating clients with depression, anxiety and PTSD with psychedelic ketamine therapy. He also serves as the Health & Safety Director and a state licensed psilocybin facilitator at the Innertrek service center in Portland, Oregon. In this conversation, Dr. Mehr outlines key risk categories for psilocybin therapy: medical conditions, medication interactions, and mental health history. He emphasizes the importance of individualized safety planning over binary yes/no decisions. Dr. Mehr discusses specific considerations such as cardiovascular issues, diabetes, serotonergic medications, substance use disorders, suicidal ideation, and family history of psychosis. The conversation also covers strategies for mitigating risk, including delaying treatment, contingency plans, improving support systems, and ensuring informed consent. Throughout, Dr. Mehr stresses a collaborative, nuanced approach that balances potential benefits with careful preparation and personalized care.   In this episode, you'll hear: Stories from Dr. Mehr's practice of helping patients with different conditions and histories ensure safe psilocybin experiences Interactions between GLP-1 agonists and psilocybin How Dr. Mehr works with patients who have family histories of psychosis Harm reduction practices which leverage other psychedelics or non-psychedelic interventions to help prepare a client for a psilocybin session Why insulin dependent diabetes can be a contraindication for psychedelic therapy What medication combinations can increase the risk of serotonin toxicity with psilocybin  Supporting clients experiencing spiritual emergency following psilocybin therapy Safety considerations when working with clients who have a history of seizures The importance of having contingency plans if medical emergencies arise during psilocybin therapy The intricacies of providing fully informed consent for psychedelic therapy   Quotes: "There is some evidence now that taking a single serotonergic agent—say, taking Lexapro—and no other medications that increase the risk of serotonin toxicity seems safe where I am not at this point recommending that people stop, skip, or taper a single SSRI in preparation for a psilocybin session due to safety." [12:20] "One of the difficulties with making these decisions or speaking with some confidence or authority on the matter is that the clinical trials that have been done largely exclude people with lots of conditions—family history and specifically first degree relatives with history of psychosis and bipolar disorder… So we have anecdotal evidence, we have population based surveys to go by. And so when I talk to clients about this, I speak from a place of humility." [27:30] "I always emphasize to clients that while we're talking about a specific safety issue like serotonin toxicity, we don't want to trade that for psychological instability and crisis and declare success because we've helped somebody taper off of a medication that seems less safe and now they aren't sleeping, they're agitated, they're depression is worse, their suicidality is worse. So we have to take a holistic approach to this and consider the totality of what's happening with that client."  [36:45] "There are so many different components to trying to set somebody up for success rather than a yes/no, black and white approach [to psilocybin therapy]." [48:44]   Links: Cascade Psychedelic Medicine website InnerTrek website Managing Medical Risk In Patients Seeking Psilocybin Therapy CME/CE Course Psychedelic Medicine Association Porangui  

In this episode, Monnica T. Williams, PhD, ABPP joins to discuss how psychedelics may help alleviate mental health impacts of racial trauma. Dr. Williams is a licensed clinical psychologist and professor at the University of Ottawa in the School of Psychology, where she is the Canada Research Chair in Mental Health Disparities. In this conversation, Dr. Williams begins by highlighting the daily stress and trauma experienced by people of color, likening it to PTSD. She discusses a survey her team conducted which revealed that many people of color use psychedelics to manage racial trauma, showing significant reductions in stress, depression, and anxiety. Additionally, Dr. Williams emphasizes the importance of a safe environment and culturally competent therapists. In closing, she discusses ongoing research at this intersection and the need for more funding and awareness in this field.   In this episode, you'll hear: How racial trauma manifests as conditions like PTSD, depression, and anxiety The importance of an intersectional perspective Current treatments for mental health struggles stemming from racial trauma Results from Dr. Williams' research into psychedelic use amongst people of color The importance of safe and supportive settings for psychedelic experiences How shared life experiences between a therapist and client can strength the therapeutic alliance and improve outcomes Why bias training is particularly important in the context of psychedelic therapy   Quotes: "People of color who live in these white dominated Western contexts are continually bombarded by subtle —and not so subtle—messages about their worth, about their standing in society, about their intelligence, their character, on and on and on and on. And so really the daily onslaught just wears and wears away at people, and the stress of that can actually become traumatizing." [1:49] "People heal from trauma when someone witnesses their pain, right? When people can compassionately witness your pain and join in it with you—this is the basis behind all therapeutic approaches for trauma treatment." [10:13] "We saw [from our survey study] that many, many people of color are using psychedelics to manage racism, often very quietly. But it seems for many people to be quite effective and quite helpful." [11:53] "We looked at some separate psychedelics where we had enough people who described a specific one like psilocybin or LSD or peyote in some cases. And so we were able to look at those psychedelics separately and we didn't actually find a difference. It didn't seem to matter which psychedelic it was. It seemed that they were all, more or less equally effective." [15:20]   Links: Dr. Williams' website Dr. Williams on X Dr. Williams on Instagram Dr. Williams on LinkedIn Dr. Williams' study "Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and Canada" Behavioral Wellness Clinic - Connecticut Behavioural Wellness Clinic - Ottawa  Masters Program in Psychedelics and Consciousness Studies at University of Ottawa Psychedelic Medicine Association Porangui

In this episode, Robin Carhart-Harris, PhD joins to elucidate the intersection of psychedelics and neuroplasticity. Dr. Carhart-Harris is the Ralph Metzner Distinguished Professor in Neurology and Psychiatry at the University of California, San Francisco. Robin founded the Centre for Psychedelic Research at Imperial College London in April 2019, was ranked among the top 31 medical scientists in 2020, and in 2021, was named in TIME magazine's '100 Next' – a list of 100 rising stars shaping the future. Dr. Carhart-Harris begins by discussing the impact of psychedelics on neuroplasticity and mental health. He explains neuroplasticity as the brain's ability to change, emphasizing its role in mood disorders and substance use and describes how stress atrophies the brain, leading to mental illness. Dr. Carhart-Harris differentiates between neuroplasticity and neurogenesis, noting that while neurogenesis is limited in adults, neuroplasticity can be influenced by psychedelics like ketamine, psilocybin, and MDMA. In closing, he also discusses the entropic brain hypothesis, suggesting that increased brain entropy leads to richer subjective experiences.    In this episode, you'll hear: The relationship between neuroplasticity and "canalization"  Why homeostatic neuroplasticity may promote mental wellbeing Differences between ketamine, MDMA, and serotonergic psychedelics in terms of neuroplasticity The details of the entropic brain hypothesis Psychedelics' effect on the default mode network The frontiers of research into psychedelics and neuroplasticity  Quotes: "So changeability is what plasticity is. And neuroplasticity—that's the ability of the brain to change. Okay, and how is neuroplasticity related to mood disorders like depression and anxiety or substance use disorder or something like that? Well, that's a great question cause we don't have it entirely nailed down. But one of the most reliable findings in biological psychiatry is that stress atrophies the brain." [2:47] "The main thing with ketamine is that the window of increased plasticity is brief… That makes sense because that reflects how ketamine seems to work therapeutically—that it provides relief somewhat short-term, unless it is twinned with, say, psychotherapy or you do repeat administration and get someone out of the rut they were in." [22:15] "We've seen in people with depression, brain networks can become quite segregated from each other—they are ordinarily, they're quite functionally separate and distinct—but that modularity might be a bit elevated in depression. But what we've seen with psilocybin therapy is that separateness between systems, that segregated quality of organization of brain networks, brain systems actually decreases after psilocybin therapy for depression. I'll put it another way: the brain looks more globally interconnected after psilocybin therapy for depression and the magnitude of that… correlates with improvements." [39:19]   Links: Carhart-Harris Lab website Dr. Carhart-Harris on X Dr. Carhart-Harris' 2025 article: "Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models" Dr. Carhart-Harris' 2012 article: "Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin" Dr. Carhart-Harris' 2010 article with Karl Friston: "The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas" Psychedelic Medicine Association Porangui

In this episode, Dori Lewis, MA, MEd, LPC-S discusses the common myths and misconceptions surrounding psilocybin for healing. Dori is a psychotherapist, co-founder of Elemental Psychedelics, and owner of Reflective Healing in Fort Collins, CO, who specializes in psychedelic-assisted therapy, blending transpersonal psychology with spiritual practices. With experience facilitating ketamine sessions and training clinicians, she advocates for ethical standards in psychedelic medicine while championing a feminine-centered approach to facilitator training. The first myth that Dori addresses in this conversation is the idea that it is the psilocybin mushroom itself that does all the healing work. Contrary to this common misconception, Dori suggests that it is the client's own initiative working in tandem with the mushroom that really spurs healing. She also emphasizes that there are not any set protocols for how often psilocybin should be taken for healing, instead suggesting that clients should be guided to attune to their own internal intuition to determine when a psilocybin journey may be particularly helpful.  Another misconception Dori addresses is that healing with psilocybin can occur without causing deep transformations in one's identity or shifts in one's worldview. She suggests facilitators must be very transparent about these possible impacts to best prepare clients for these kinds of major changes that psilocybin can catalyze. In closing, Dori reiterates that clients should be supported and prepared to encounter intense emotional experiences with psilocybin, as some of the most difficult psychedelic journeys can actually be the most healing.   In this episode, you'll hear: The biggest myths and misconceptions Dori encounters working with clients in her practice The importance of a relational understanding of psychedelic healing The specific types of trauma where psilocybin may be a particularly effective healing modality  The training for psilocybin facilitators in Colorado under the Natural Medicines Program and the importance of scope of practice Why some people's mental health gets worse before it gets better following a psilocybin experience What can cause lack of response to psilocybin therapy and how better preparation can often mitigate this   Quotes: "Mushrooms are amazing and they can help us in our healing journey. But they are one tool in a mosaic of other tools that we can use to help ourselves heal and grow and change." [6:54] "I don't really know where this message came from—that mushrooms cure PTSD—but that is a huge myth. They can help—with certain types of trauma within the context of a healthy therapeutic relationship with a skilled provider, yes, at times when it is right. But ultimately the best medicine for trauma is going to be MDMA—and ketamine." [18:18] "It is the responsibility of providers and facilitators to inform clients of the realistic expectations they should have for their [psychedelic] journeys—and that is also an ethical need and something that facilitators need to consider through an ethical lens." [25:20] "There's a lot to be said about the unique ways that mushrooms express through our bodies and through our minds and through our hearts that give us information about where we are at and where we need to work or continue to work in order to access the healing we so desire." [37:34]   Links: Dori on LinkedIn Elemental Psychedelics on LinkedIn Elemental Psychedelics website   Previous episode: Integrating Challenging Psychedelic Experiences with Keith Kurlander, MA Previous episode: The Challenging Psychedelic Experiences Project with Jules Evans Previous episode: The Dangers of "Ayahuasca Told Me…" with Jerónimo Mazarrasa Psychedelic Medicine Association Porangui  

In this episode, Jodie NewDelman, PsyD joins to discuss the benefits and risks of leveraging psychedelics for professional growth. For over three decades, Dr. NewDelman has been an executive consultant, health system advisor, licensed psychologist, and clinical supervisor. She is also trained and certificated in psychedelic medicine and has been working with growth-oriented professionals developing greater alignment between their leadership roles at work and their personal lives. In this conversation, Dr. NewDelman discusses the typical struggles people experience in their professional lives and where psychedelic experiences may provide insight and empowerment to become more aligned with one's work. She unpacks the psychological experience of being "stuck," something that psychedelics may specifically help overcome.  Beyond individualistic approaches to professional growth, Dr. NewDelman also discusses the importance of humanizing the workforce and how conscious leadership is crucial to achieve this goal. In closing, Dr. NewDelman warns against the danger of trying to implement radical changes after a psychedelic experience without sufficient integration, emphasizing the importance of a holistic approach to this work.    In this episode, you'll hear: Navigating feelings of imposter syndrome and experiences of marginalization The importance of work life balance and how to psychedelic experiences can empower reflection on this topic Why clear intention is crucial for leveraging psychedelic experiences for professional growth The danger of spiritual bypassing after profound psychedelic experiences   Quotes: "No matter who you are, you're going to have your own set of intentions. The intentions will be bespoke. And maybe you don't know the first or second time what you want to work on when you go into it—an experiential medicine session. But eventually we can narrow those themes down to what it is that we really need insight on." [22:01] "if you need to focus on some nitty gritty, annoying detail [at work], no matter how transcendent your perspective is in your psychedelic medicine session, you still have to do the thing at work. You still have to make the practical changes. So we need to kind of stay tethered to reality in that way." [38:58] "Our tendency is to avoid pain, right? We want to go away from the obstacles. And if psychedelics teach us nothing else, it's that we need to go through the storm. We need to turn toward the issue." [40:25]   Links: Essensuate website Essensuate on Instagram Essensuate on LinkedIn   Essensuate on Facebook  What Are The Habits of Mind? - The Institute for the Habits of Mind Previous episode: Psilocybin for Addressing Burnout with Tracy Kim Townsend, MD Psychedelic Medicine Association Porangui Email: jodie@essensuate.com

In this episode, Tracy Kim Townsend, MD, joins to discuss the potential efficacy of psilocybin therapy for addressing burnout, particularly in healthcare professionals. Dr. Townsend is a Harvard-trained medical doctor, licensed psilocybin facilitator, and the Co-Founder & CEO of Meadow Medicine, one of the only legal psilocybin service centers based in the U.S., founded and led by an MD. In this conversation, Dr. Townsend gives an overview of burnout and discusses its prevalence amongst healthcare professionals due to the intense nature of these professions. She mentions the relevance of the wounded healer archetype for many physicians and how this identity can intersect with experiences of burnout. Turning to psilocybin therapy, Dr. Townsend discusses how these psychedelic treatments can help address burnout through promoting neuroplasticity and facilitating effective emotional processing. Following these experiences, patients are often much better poised to make well-considered life changes to help stave off burnout. Dr. Townsend concludes by emphasizing the importance of integration following psychedelic journeys to ensure maximal benefit and effectiveness of these treatments.    In this episode, you'll hear: How burnout develops How technology and culture have contributed to the rise of burnout The symptoms of burnout Supporting career longevity for physicians How psilocybin may support patients looking to address burnout Clinical research into psilocybin for burnout in healthcare professionals Why loosening the grip on one's identity and ego dissolution may be tied to the therapeutic benefits of psychedelics   Quotes: "One core area that I see psilocybin playing a role [for addressing burnout] is just creating these spaces where we can process emotions and integrate them." [21:41] "SSRIs, which are the gold standard intervention right now for depression, usually result in about a nine-point drop [in depression scores on the Montgomery-Åsberg Depression Rating Scale], which is really no better than placebo… Whereas psilocybin showed a three-fold drop—there's really no intervention for depression we see with that dramatic of results." [25:17] "Another thing that I think is remarkable, too is… you continue to see the benefits—if you check scores immediately after the [psilocybin] journey and then at six months out, there continues to be improvement in mental health scores." [29:06]   Links: Dr. Townsend on Instagram Dr. Townsend on X Meadow Medicine website  "Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial" by Anthony L. Back, MD et al. Psychedelic Medicine Association Porangui  

In this episode, Christina P. Kantzavelos, LCSW, MSW, MLIS joins to discuss the use of psychedelics to address chronic illness. Christina is an international psychotherapist, coach, writer and artist, who specializes in treating clients with chronic illness, and complex trauma utilizing various modalities, including psychedelic assisted therapy. In this conversation, Christina overviews the complex mental and physical health impacts of chronic pain conditions and shares her expertise on psychedelic and non-psychedelic treatments for these conditions. Christina mentions that chronic pain can put one's body in a state that encourages fight, flight, freeze, and fawn responses which can disempower the patient's efforts to address their condition. She also explores the intersection of identity and chronic pain conditions, discussing how that while receiving a particular diagnosis can be helpful and affirming, taking this as a core part of one's identity can also be a major roadblock to healing. In closing, Christina emphasizes that pain starts in the brain, so leveraging neuroplasticity through psychedelics and other means can be a particularly powerful way to address both physical and mental health aspects of chronic pain conditions.    In this episode you'll hear: How Christina got involved in working with patients with chronic pain The common mental health presentations in those with chronic pain The importance of addressing physical health and mental health concurrently  Why psychedelics may be helpful for addressing chronic pain conditions The immunomodulating effects of psychedelics The power of neuroplasticity for addressing chronic pain  Utilizing neural retraining and microdosing in conjunction to prepare for more successful higher dose psychedelic experiences   Quotes: "I use all kinds of modalities and I don't just treat someone's depression or anxiety or complex trauma—I see it as everything is interwoven and related to each other. And it's important that we look at the entirely mosaic piece rather than just focusing on one area." [5:20] "There is a state of empowerment versus disempowerment in identifying with our chronic illness. I'm not saying that it is not real and it's not happening to you but it definitely is not you. It's something you are experiencing. Even if it's chronic and lifelong, it's still something you are experiencing—it's not you as a whole." [17:48] "I've noticed that any of my clients who have gone through neural retraining have had little to no bad [psychedelic] trips which is amazing and I feel like that's partly because they worked so hard to resource themselves in advance." [25:19]   Links: Christina on Instagram Christina on LinkedIn Begin with Today website When the Body Says No: The Cost of Hidden Stress by Gabor Maté PMA CME/CE accredited course: Managing Medical Risk in Patients Seeking Psilocybin Therapy Search for providers on the Psychology Today website Psychedelic Medicine Association Porangui  

In this episode, Jerónimo Mazarrasa joins to discuss how to interpret visions and insights disclosed during ayahuasca journeys more effectively. Jerónimo is Program Director at ICEERS, founder of ICEERS Academy, and creator of AyaSafety, an online course for people interested in increasing the safety of ayahuasca ceremonies. To start, Jerónimo emphasizes that answering the question of whether ayahuasca visions originate in the plant medicine itself or if these are just disclosures of one's own subconscious is actually not what's most important. Instead, he suggests that in either case, what is crucial is spending time carefully considering how one should respond to these disclosures. Jerónimo shares insights from expert facilitators on how one can best go about interpreting and responding to such experiences, suggesting that an important aspect of this process is that participants feel comfortable taking personal responsibility for whatever decisions they eventually decide to make rather than thinking of these major life changes as necessary consequences of the psychedelic experience itself. In closing, Jerónimo discusses the tension between externalization and psychologization of psychedelic experiences and why both of these can lead to issues.    In this episode, you'll hear: The common experience of feeling as though the ayahuasca has communicated something to you Examples of where taking an ayahuasca vision literally can lead to problematic outcomes  The "three confirmations" one should look for before making a major decision based on a psychedelic experience The metaphor of ayahuasca as a microscope How skilled ayahuasca facilitators ensure proper psychological hygiene with participants Judging the validity of potential repressed memories that seem to surface during psychedelic experiences   Quotes: "The way that ayahuasca becomes useful for people, I think, is that it shows you—it amplifies and shows you—what is already inside of yourself. Now, this is very useful for certain things but one has to understand the nature of the language."  [9:23] "Facilitators should instruct their participants that one rule is that you shouldn't make any decisions during an ayahuasca ceremony—unless they are decisions related to taking yourself out of danger." [14:42] "Ayahuasca is not a shortcut for personal development—it's just a flashlight that can help you shed some light on some darker parts of [your] issues and problems, but it is not a shortcut." [35:47] "The main contraindication of psychedelics is not wanting to take psychedelics. You should absolutely never ever ever ever ever take psychedelics if you don't want to because it is going to be horrible. It's like a kiss—when you want it, its beautiful, intimate, gorgeous; when you don't want it, it's the most intrusive, disgusting, blech thing ever." [50:27]   Links: Jerónimo on Instagram Jerónimo on Facebook ICEERS Academy website ICEERS Academy on Instagram AyaSafety course  Previous episode: Guruism and Cult Dynamics in Psychedelic Practices with Joseph Holcomb Adams Previous episode: Can Psychedelics Lead to False Beliefs? with Hugh McGovern, PhD Psychedelic Medicine Association Porangui

In this episode, Hugh McGovern, PhD joins to discuss his research on the impact of psychedelics on beliefs. Dr. McGovern is a Research Fellow at the School of Medicine, Deakin University, Melbourne, Australia. To start, Dr. McGovern introduces the inference or predictive processing framework utilized in his paper "An Integrated theory of false insights and beliefs under psychedelics". He explains the role of prediction in cognition, showing how insights occur when our existing perspectives are unable to make sense of our experience. In this vein, Dr. McGovern discusses how the psychedelic experience disrupts our normal modes of prediction and perception, leaving room for greater influence of environmental factors on insight production. In closing, Dr. McGovern shares ideas on further clinical directions for this research that could give guidance for helping patients more effectively integrate insight experiences.   In this episode you'll hear: The research into how psychedelics can influence and change beliefs The role beliefs and insights can play in psychedelic journeys  How false insights can be experimentally induced The connection between prediction errors in our cognition and insight experiences The hippocampus, memory, and psychedelics The association between insight moments and increased mental health following psychedelic experiences   Quotes: "[In psychedelic experiences] your expectations are no longer helping you make sense of your current sensory experience. And so you're uniquely susceptible to environmental input under psychedelics—which would account for things like visual hallucinations [and] these novel insight moments." [18:30] "When you have really really strong prediction errors or really really strong insight moments, they can have a disproportionately important influence on your worldview going forward." [20:03] "Psychedelics, from a few different studies, show they can impair the formation of hippocampally dependent memories but they can perhaps even enhance the formation of cortically dependent memories. So what that means is you come out of the experience with this sense of knowing but it's in some sense lacking in details." [29:04]   Links: "An Integrated theory of false insights and beliefs under psychedelics" by Hugh McGovern et al. Dr. McGovern on Bluesky Previous episode: Guruism & Cult Dynamics in Psychedelic Practices with Joseph Holcomb Adams Psychedelic Medicine Association Porangui